If PTSD is keeping you awake, or you are worried about someone you love who lives with it, the ibogaine headline probably raised one question first: does this money change anything for you? It does not pay for patient trials. The U.S. government’s Advanced Research Projects Agency for Health (ARPA-H) committed up to $4.9 million over five years to lay groundwork for the first U.S. clinical trials of ibogaine for serious mental illness, and The National Desk reports that ibogaine remains illegal in the United States.
Affiliate disclosure: You will find affiliate links on this page. This site may receive a commission on purchases made through them.
Quick facts, dated 2026-11-13
| Question | What the reports say | Source and date |
|---|---|---|
| Amount | Up to $4.9 million over five years | ARPA-H announcement, Nov. 12, 2026; The National Desk, Nov. 12, 2026 |
| Who receives it | Beond, Inc.; Mark Cuban Cost Plus Drug Company, PBC | ARPA-H announcement, Nov. 12, 2026 |
| What it pays for | Groundwork for future trials: trial framework, data and experimental drug products meant to support future IND applications to FDA | ARPA-H announcement, Nov. 12, 2026 |
| What it does not pay for | Patient trials, according to Health Secretary Robert F. Kennedy Jr. | The National Desk, Nov. 12, 2026 |
| Legal status in the U.S. | Illegal, in the same highly restricted drug class as LSD and ecstasy; no current IND to conduct clinical research on ibogaine as a psychiatric treatment | The National Desk, Nov. 12, 2026; ARPA-H announcement, Nov. 12, 2026 |
| Legal status in Mexico | Not illegal; clinics there treat patients | The National Desk, Nov. 12, 2026 |
| Main safety concern reported | Can trigger potentially deadly irregular heart rhythms | The National Desk, Nov. 12, 2026 |
| Americans with serious mental illness (estimate) | 14 million or more | ARPA-H announcement, Nov. 12, 2026 |
How much is ARPA-H putting into ibogaine, and who gets it?
ARPA-H’s announcement, published November 12, 2026, sets the commitment at up to $4.9 million over five years. Awards vary by awardee and depend on each team meeting milestones ARPA-H describes as aggressive. Two recipients are named:
- Beond, Inc. is collecting clinical data on ibogaine’s safety, dosing, efficacy and durability.
- Mark Cuban Cost Plus Drug Company, PBC is building the regulatory, clinical, chemical and engineering foundation for a domestically manufactured, single-molecule ibogaine hydrochloride product for potential PTSD treatment.
The National Desk adds that Beond is a Texas-based company that has treated more than 3,000 patients with ibogaine in Mexico.
What does the funding actually pay for?
ARPA-H says the money is meant to establish the clinical trial framework needed to study ibogaine for mental illness, and to generate high-quality data and experimental drug products that support future Investigational New Drug (IND) applications to FDA. The National Desk, citing Health Secretary Robert F. Kennedy Jr., reports that the money pays for manufacturing the drug, determining doses and designing studies. It will not pay for patient trials. Kennedy also said future funding could explore addiction uses.
ARPA-H describes this as groundwork that may lead to those steps. A separate effort, named ASCENT-IBO, is still being evaluated, with proposals under review, and would build on these results to accelerate Phase 1 and 2 trials.
What does ibogaine do for PTSD, according to the research so far?
ARPA-H describes the current evidence as anecdotal. It says anecdotal evidence from international clinics suggests ibogaine “may provide rapid psychiatric symptom relief in some individuals.” The National Desk reports that unnamed veterans groups and advocates say ibogaine “may help” with PTSD, severe depression and opioid addiction. ARPA-H’s Al Bugazia, M.D., Senior Advisor for Special Projects, who leads the effort, said “Reports of successful ibogaine treatments are too promising to ignore,” and that the goal is results “in years, not decades.”
What is the success rate of ibogaine treatment?
Success is what the funded studies are meant to measure. Beond’s work will collect data on safety, dosing, efficacy and durability, and ARPA-H frames what comes next as conditional, using the words “If successful.” Any number you see online should be checked against the study that produced it. A plain checklist for that is in reading mental-health research headlines.
Is ibogaine legal?
No, ibogaine is still illegal in the United States. The National Desk reports it sits in the same highly restricted drug class as LSD and ecstasy. ARPA-H says there is no current IND to legally and safely conduct clinical research on ibogaine as a psychiatric treatment in the United States. The new work is meant to help make first U.S. clinical trials possible, and ARPA-H ties the effort to Executive Order 14401.
Texas has its own program. A Texas Tribune story, republished by Marijuana Moment, reports that Texas will use $50 million the Legislature invested to run its own ibogaine research after state officials couldn’t find a company to help develop it into a drug for Food and Drug Administration (FDA) approval. The same story says, “Ibogaine is an illegal drug.”
The National Desk reports that ibogaine is not illegal in Mexico, where clinics treat patients.
What are the heart and safety risks?
The National Desk reports that ibogaine can trigger potentially deadly irregular heart rhythms, which it describes as a key reason research has moved slowly. The same article lists intense hallucinations, nausea, vomiting and tremors. ARPA-H says the Beond work will evaluate ibogaine’s safety.
Who is quoted, and what did they say?
| Who | Role | What they said |
|---|---|---|
| Al Bugazia, M.D. | Senior Advisor for Special Projects, ARPA-H; leads the effort | “Reports of successful ibogaine treatments are too promising to ignore.” The goal is results “in years, not decades.” (ARPA-H announcement, Nov. 12, 2026) |
| Robert F. Kennedy Jr. | Health Secretary | Funding will not pay for patient trials; future funding could explore addiction uses. (The National Desk, Nov. 12, 2026) |
| Doug Collins | Veterans Affairs Secretary | The effort would focus first on safety and research quality. (The National Desk, Nov. 12, 2026) |
| Unnamed veterans groups and advocates | Not named in the article | Ibogaine “may help” with PTSD, severe depression and opioid addiction. (The National Desk, Nov. 12, 2026) |
Key dates
| Date | What happened | Source |
|---|---|---|
| 2025 | Gov. Greg Abbott signed Senate Bill 2308, creating a consortium of universities, hospitals and drug developers to conduct clinical trials of an ibogaine drug | Texas Tribune story, republished by Marijuana Moment |
| March 31, 2026 | Joint statement by Lt. Gov. Dan Patrick and House Speaker Dustin Burrows: Texas will use $50 million to run its own ibogaine research program | Texas Tribune story, republished by Marijuana Moment |
| April 2026 | President Trump’s executive order directs agencies to speed psychedelic research and review; ARPA-H ties its effort to Executive Order 14401 | The National Desk; ARPA-H announcement |
| Nov. 12, 2026 | ARPA-H announces up to $4.9 million over five years for ibogaine groundwork | ARPA-H announcement |
Common mix-ups in the headlines
- $4.9 million, not $49 million. ARPA-H and The National Desk both state up to $4.9 million. If you see “49 million” elsewhere, use the ARPA-H figure.
- The federal award is not the Texas money. ARPA-H’s up to $4.9 million is a federal award. Texas’s $50 million is a separate state program under Senate Bill 2308.
- Groundwork is not patient care. The money prepares studies, and Kennedy says it does not pay for patient trials.
- Legal in Mexico is not legal here. The National Desk reports ibogaine is not illegal in Mexico, but it remains illegal in the U.S.
- Funding is not approval. ARPA-H describes the work as groundwork for future steps, not a finished regulatory decision.
Who should you ask about PTSD care?
Ask your prescriber or doctor about the PTSD care that is available to you, and ask a pharmacist about any medicine you take. The USA.gov mental health help page lists mental health services for veterans and their family members, which it says can help with depression, PTSD and other issues. If you have Medicare, Medicare’s mental health coverage page lists covered services, including outpatient counseling and psychotherapy. Bring your questions with you, and preparing for a mental health conversation covers the goals and questions to bring.
In a crisis, call or text 988, the Suicide and Crisis Lifeline. Veterans can dial 988 and press 1 for the Veterans Crisis Line. Call 911 for an immediate medical crisis.
Other questions in this search
ARPA-H’s announcement estimates 14 million or more Americans with serious mental illness. Mental health statistics in headlines explains how to read numbers like that.
Questions about federal mental health spending, which presidents changed it, which condition is most severe or most fatal, and the rarest disorders go beyond this story. For federal grant records, USAspending.gov tracks awards by project. For definitions of serious mental illness and how conditions compare, ask your clinician or check the National Institute of Mental Health’s website.
Questions to take to your next appointment
- Which PTSD care is available to me now, and what does my coverage pay for?
- Does any heart condition or medicine I take need a clinician’s review?
- Who near me offers PTSD care, and what is the plan if things get worse?
Writing these down before you go makes the first conversation easier.
By the Global MH Summit Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.